DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Drugs Made In America Acquisition II Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.18−0.00 (-0.05%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
46M
Shares held, 13F filers
Institutional holders
69
5 new, 4 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Drugs Made In America Acquisition II LLC | 6,708,333 | 10.20% | 13D (active) | Oct 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DMII | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Karpus Management, Inc. | 2,787,998 | – | $28.05M | +190,075 | 0.81% |
| Magnetar Financial LLC | 2,700,000 | – | $27.16M | – | 0.25% |
| MMCAP International Inc. SPC | 2,700,000 | – | $27.16M | – | 2.30% |
| Glazer Capital, LLC | 2,343,278 | – | $23.57K | −6,483 | 0.58% |
| Highbridge Capital Management LLC | 2,241,215 | – | $22.57M | +2,016,211 | 0.55% |
| Millennium Management LLC | 1,993,558 | – | $20.06M | +17,133 | 0.01% |
| Hudson Bay Capital Management LP | 1,969,030 | – | $19.81M | – | 0.05% |
| Wolverine Asset Management LLC | 1,855,222 | – | $18.66M | +59,931 | 0.16% |
| Polar Asset Management Partners Inc. | 1,500,000 | – | $15.09M | – | 0.25% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 1,500,000 | – | $15.09M | – | 0.21% |
| D. E. Shaw & Co., Inc. | 1,475,000 | – | $14.84M | +84,900 | 0.01% |
| AQR Arbitrage LLC | 1,131,266 | – | $11.38M | +18,876 | 0.16% |
| Aristeia Capital LLC | 1,100,000 | – | $11.07M | – | 0.14% |
| Crossingbridge Advisors, LLC | 1,100,000 | – | $11.07M | +750,000 | 1.95% |
| First Trust Capital Management L.P. | 1,067,798 | – | $10.74M | – | 0.63% |
| Davidson Kempner Capital Management LP | 1,000,000 | – | $10.06M | – | 0.12% |
| OMERS ADMINISTRATION Corp | 1,000,000 | – | $10.06M | – | 0.06% |
| Picton Mahoney Asset Management | 888,000 | – | $8.93M | +13,000 | 0.07% |
| Two Sigma Investments, LP | 886,544 | – | $8.92M | – | 0.01% |
| Moore Capital Management, LP | 750,000 | – | $7.55M | – | 0.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | 46M | 5 / 15 | 14 / 4 | 6M | 4M |
| Q1 2026 | 68 | 44M | 19 / 11 | 16 / 2 | 12M | 3M |
| Q4 2025 | 51 | 35M | 51 / 0 | 0 / 0 | 35M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DMII | Value | % of fund | As of |
|---|---|---|---|---|---|
| CrossingBridge Low Duration High Income Fund | 1,073,700 | – | $10.80M | 0.60% | Jun 30, 2026 |
| First Trust Merger Arbitrage Fund | 913,211 | – | $9.19M | 0.56% | Jun 30, 2026 |
| First Trust Multi-Strategy Fund | 142,639 | – | $1.43M | 0.11% | Jun 30, 2026 |
| Destinations Low Duration Fixed Income Fund | 26,300 | – | $264.58K | 0.09% | May 31, 2026 |
| Global Multi-Strategy Fund | 14,179 | – | $142.64K | 0.03% | May 31, 2026 |
| The SPAC and New Issue ETF | 10,769 | – | $108.34K | 1.32% | Jun 30, 2026 |
| Robinson Opportunistic Income Fund | 10,000 | – | $100.60K | 0.94% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Lynn Stockwell | CEO and Exe. Chair of Board, Director, 10% owner | 14,675,000 | Oct 1, 2025 |
| Glenn C. Worman | CFO | 100,000 | Oct 1, 2025 |
| Catherine Do | Director | 100,000 | Oct 17, 2025 |
| Myron W. Shulgan | Director | 100,000 | Oct 2, 2025 |
| Sridhar G. Prasad | Director | 100,000 | Oct 1, 2025 |
| Made In America Acquisition II LLC Drugs | 10% owner | 6,708,333 | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Catherine Do Director | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Myron W. Shulgan Director | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Sep 26, 2025 | Other | −400,000 | – | – | 14,675,000 |
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Sep 26, 2025 | Sale | −7,966,667 | – | – | 6,708,333 |
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Sep 26, 2025 | Buy | +700,000 | – | – | 15,075,000 |
| Sridhar G. Prasad Director | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Glenn C. Worman CFO | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Made In America Acquisition II LLC Drugs 10% owner | Sep 26, 2025 | Sale | −7,966,667 | – | – | 6,708,333 |
| Made In America Acquisition II LLC Drugs 10% owner | Sep 26, 2025 | Other | −400,000 | – | – | 14,675,000 |
| Made In America Acquisition II LLC Drugs 10% owner | Sep 26, 2025 | Buy | +700,000 | – | – | 15,075,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.